Lung and Prostate Cancer Drugs to be watched in 2013
OncoGenex and Teva are evaluating OGX-011, an antisense cancer drug created with our technology in three phase 3 studies, and they remain on track to report phase 3 data in prostate cancer this next year.
OncoGenex is also evaluating another antisense drug that we licensed to them, OGX-427, in phase 2 studies in patients with prostate and metastatic bladder cancers. We are finishing the phase 2 evaluation of our EIF4E inhibitor in patients with lung and prostate cancers. We expect to report data from those studies next year.